Literature DB >> 15750633

p53 must be competent for transcriptional regulation to suppress tumor formation.

Monica Nistér1, Mengjia Tang, Xiao-Qun Zhang, Chaoying Yin, Michelle Beeche, Xinrong Hu, Gunilla Enblad, Terry van Dyke, Geoffrey M Wahl.   

Abstract

In vitro studies suggest that effective tumor suppression by p53 requires multiple domains to execute transcription-dependent and transcription-independent functions. We generated a mutant p53 allele in mice, p53(W25QL26S) (p53(QS)), containing an inactive transactivation domain to evaluate the importance of transactivation for p53-mediated tumor suppression. Recently, we discovered that the allele also contains a valine substitution for alanine at codon 135, which borders the DNA-binding domain. We found that p53(QSval135) bound to chromatin albeit less well than p53(QSala135), but both were equally deficient in transcriptional regulation, apoptosis induction in mouse embryo fibroblasts (MEFs), and suppression of tumor formation by E1A, Ha-Ras transformed MEFs. p53(QSval135) mice and p53-null mice exhibited identical tumor development kinetics and spectra in spontaneous and oncogene-initiated tumorigenicity assays, when tested in a homo- and heterozygous configuration. The p53(QSval135) allele did not have dominant negative functions and behaved as a null allele. Taken together, these data indicate that effective tumor suppression requires the transcriptional regulation function of p53, and they suggest that transactivation independent functions of p53 are unlikely to contribute significantly to tumor suppression in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750633     DOI: 10.1038/sj.onc.1208354

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Characterization of functional domains necessary for mutant p53 gain of function.

Authors:  Wensheng Yan; Xinbin Chen
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

Review 2.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

3.  Mdm2 and Mdm4 loss regulates distinct p53 activities.

Authors:  Juan A Barboza; Tomoo Iwakuma; Tamara Terzian; Adel K El-Naggar; Guillermina Lozano
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

4.  The transcriptional regulatory function of p53 is essential for suppression of mouse skin carcinogenesis and can be dissociated from effects on TGF-beta-mediated growth regulation.

Authors:  Roshini M Ponnamperuma; Kathryn E King; Tamador Elsir; Adam B Glick; Geoffrey M Wahl; Monica Nister; Wendy C Weinberg
Journal:  J Pathol       Date:  2009-10       Impact factor: 7.996

5.  Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Authors:  Stian Knappskog; Ranjan Chrisanthar; Erik Løkkevik; Gun Anker; Bjørn Østenstad; Steinar Lundgren; Terje Risberg; Ingvil Mjaaland; Beryl Leirvaag; Hrvoje Miletic; Per E Lønning
Journal:  Breast Cancer Res       Date:  2012-03-15       Impact factor: 6.466

6.  p53 activates transcription by directing structural shifts in Mediator.

Authors:  Krista D Meyer; Shih-Chieh Lin; Carrie Bernecky; Yuefeng Gao; Dylan J Taatjes
Journal:  Nat Struct Mol Biol       Date:  2010-05-09       Impact factor: 15.369

7.  CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Authors:  Ranjan Chrisanthar; Stian Knappskog; Erik Løkkevik; Gun Anker; Bjørn Østenstad; Steinar Lundgren; Elisabet O Berge; Terje Risberg; Ingvil Mjaaland; Lovise Maehle; Lars Fredrik Engebretsen; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  PLoS One       Date:  2008-08-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.